Microbicide and PrEP Overview GCM Adolescent Consultation Durban, South Africa 5-6 Sept, 2007 Craig M. Wilson Adolescent Medicine Trials Network for HIV/AIDS.

Slides:



Advertisements
Similar presentations
Cristin Muecke, RMOH Nick Scott, ED AIDS NB.  Why HIV testing remains important  Treatment as prevention  Discuss advantages/disadvantages of various.
Advertisements

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
1 st step: Attachment = Same 2 nd Step: Entry = Same.
From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.
Critical linkages in prevention: HIV and STIs Jessica Justman, M.D. Center for Infectious Disease Epidemiologic Research Mailman School of Public Health,
Treating HIV with Azidothymidine (AZT) A Design by Jeanine Nasser.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
HIV and AIDS Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS).
Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
The potential and challenges of ARV-based HIV prevention: An overview
Prevention Trials in the Region Behavioral Trials* Author (Year) LocationIntervention Findings (Rate ratio (RR)) Ross (2007) Tanzania MEMA kwa Vijana,
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Topical, Oral; Daily, Intermittent; Single, Combination agents; What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of.
Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.
Virus: A biological particle composed of nucleic acid and protein Intracellular Parasites: organism that must “live” inside a host What is a Virus?
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
Microbicides: Who, what, where, when and how Rebekah Webb Global Campaign for Microbicides © Salam Dahbor,
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
The special challenges of HIV prevention trials EATG Meeting Brussels, Belgium Lori Heise Global Campaign for Microbicides.
Microbicide research in Africa: Partnership in Action Salim S. Abdool Karim, MD, PhD Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal.
XIX International AIDS Conference
HIV/AIDS BI-ANNUAL REVIEW 2008 Prevention -Goal, Indicators and Targets TACAIDS.
Biomedical Approaches to HIV Prevention HIV Research Catalyst Forum April 21, 2010, Baltimore, MD Monica S. Ruiz, PhD, MPH George Washington University.
Microbicides: Science, research, and overview of the field Dr Kamini Walia, Indian Council of Medical Research, New Delhi Bindiya Patel, Global Campaign.
ARV-based Microbicides and Resistance Jeanne Marrazzo, M.D., M.P.H. University of Washington John Mellors, M.D. University of Pittsburgh.
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
TRACK C RAPPORTEURS REPORT. Prepared by Anne BuvéBelgium Anne BuvéBelgium Sabina Bindra-BarnesIndia Sabina Bindra-BarnesIndia Saidi KapigaTanzania Saidi.
Microbicides: What will they do? What will they be like? What needs to be done? Richard A. Cone Johns Hopkins University ReProtect, LLC (“BufferGel™” &
National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
HIV Prevention : Why we need more options for women Wanjiku Kamau Consultant: International AIDS Vaccine Initiative Consultant: International Partnership.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
P1 Virology, Pathogenesis And Treatment Of HIV Infection.
JOSEPH O’REILLY Deputy Chief Executive REBEKAH WEBB Policy Officer IN COLLABORATION WITH THE GLOBAL CAMPAIGN FOR MICROBICIDES IS THERE AN INVISIBLE CONDOM.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
A Jo Robinson, Terrence Higgins Trust in cooperation with the Global Campaign for Microbicides Topical.
Microbicides: New Hope for Prevention of HIV and other STIs Pamina M. Gorbach UCLA- SPH & Medicine.
How Can Civil Society Measure Value for Money and Prove Its Worth? Amanda Glassman Center for Global Development July 26, 2012.
Top Research Priorities of STDWG Impact of a RCT of HSV-2 suppression in prevention of HIV infection (Discretionary funds--039 and R01) Association of.
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
New Hope for Clients at Risk for HIV/AIDS By William Pearson, CST LCSC BSN Candidate.
New Prevention Technologies Workshop Module 2: NPTs in context
Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.
The HIV virus. Objectives At the end of this session the participants will be able to: 1. Understand basic HIV structure 2. Describe the significance.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
Track C: Epidemiology, prevention and prevention research Quarraisha Abdool Karim (Chief Rapporteur) Team: Marian Swart, Ken Mayer, Cheryl Baxter, Ayesha.
PrEP for HIV Prevention
On behalf of The MTN-020/ASPIRE Study Team
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
AIDS supplement.
Human Health and Disease
Chapter 17a HIV infection and AIDS.
Protease.
Global Optimization of the Response to HIV
Replication life cycle of HIV and sites of antiretroviral drug action.
Presentation transcript:

Microbicide and PrEP Overview GCM Adolescent Consultation Durban, South Africa 5-6 Sept, 2007 Craig M. Wilson Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) University of Alabama at Birmingham

Interventions to Prevent HIV AVAILABLE –Behavior change (ABCs) –Condom promotion –MTCT interventions –IVDU risk reduction –STD control –Male circumcision –Post-exposure prophylaxis STILL UNPROVEN –Vaccination –Microbicides –Pre-exposure Prophylaxis –Female condoms –Treat infected partner with antiretrovirals –Abstinence only programs

Microbicides: Sites and Mechanisms Mucosal surfaces –Direct inactivation –Preservation of acidic environment –Enhancement/restoration of commensal flora –Physical barrier Tissue or Cell Surface –HIV cell receptors or co-receptors –Viral absorption or fusion Viral Surface –Polyanionic polymers or envelope interacting agents Inside Cell –Anti-retrovirals (Review: Lancet 369:787, 2007)

Microbicides: General Characteristics Potent against most HIV and other STIs Preserved activity in presence of seminal fluid No effect on integrity of mucosal surfaces No effect on commensal flora Preserve or enhance low vaginal pH Stable at tropical temperatures Compatible with latex Good acceptability: odor, color, taste, Easy to use, low cost, long shelf life

Microbicides: Trials candidates in development –One in Phase II/IIb and 3 in Phase III –11 in Phase I trials Nonoxynol (N-9) Trial –African and Thai sex workers –N-9 users with higher HIV infection rates (14.7 vs 10.3 per 100 person years) –Evidence of increased mucosal irritation

Microbicides: Trials 2 Cellulose Sulfate (Ushercell) –Polyanion with broad STI activity –3 Phase I and a Phase II trial with promising results –Two Phase III trials stopped in 2007 when the multi-country trial showed evidence of increased risk MIRA Trial (Padian et al Lancet on line 13 July, 2007) –RCC trial comparing condom alone vs condom plus diaphragm with readily available lubricant gel in South Africa and Zimbabwe –N= 5045, age 18-49, follow up planned for up to 24 months –HIV incidence of 4.1% vs 3.9% per 100 woman years in the intervention vs control arms

Microbicides: Trials 3: Active BufferGel vs PRO % Phase IIb –6 country RCT (Malawi, S Africa, Tanzania, USA, Zambia, Zimbabwe) N=3220 PRO % vs 2.0% Phase III –6 country RCT, (Cameroon, S Africa, Tanzania, Uganda, Zambia, Swaziland) N = 11,920 Carragard Phase III –South Africa 3 sites RCT, N = 6270

Microbicides: Summary Multiple products in late phase trials but success needed in one of ongoing trials to demonstrate proof of concept Will ultimately need multiple products –extended daily use vs intermittent coitally dependent use –contraceptive vs non-contraceptive –product for rectal use

Adolescent Specific Issues for Microbicides: Biological vaginal ecology and flora alteration douching/cleansing activities of population physical maturation/ectopy (non-issue if sexually active) partner acceptability

Adolescent Specific Issues for Microbicides: Trial Design Phase I/II studies: –relatively intense biomedical sampling –need sexually active populations Screening-in approaches parental permission approaches Phase II “Bridging” Studies –“Bridging” design will depend on adult data

Pre-exposure Prophylaxis (PrEP) General proof of concept comes from animal studies and MTCT ART interventions Previously not considered because of ART toxicities or unfavorable pharmacokinetics Recent availability of ART with longer half-life and lower toxicity profiles and lack of success in other approaches have re-opened considerations

HIV Replication Cycle and Sites of Drug Activity Capsid proteins and viral RNA CD4 Receptor Viral RNA New HIV particles ProteaseReverse Transcriptase Unintegrated double stranded Viral DNA Integrated viral DNA Viral mRNA Integrase gag-pol polyprotein Attachment and Fusion UncoatingReverse Transcription IntegrationTranscription Translation Assembly And Release Protease Inhibitors NRTIs NNRTIs Nucleus Cellular DNA CCR5 or CXCR4 co-receptor HIV Virions Fusion Inhibitors Adapted:Levy JA. HIV and the Pathogenesis of AIDS. 2nd ed. Washington, DC: American Society for Microbiology; 1998:9-11.

PrEP Study Designs High risk populations with exposures for risk over defined period of time –Young females in southern Africa –Commercial sex workers –IVDU while engaging in care –Discordant couples –Young MSM in US Daily/continuous vs “coitally” dependent Single drug (tenofovir) vs combination (tenofovir/FTC, Truvada)

PrEP Studies: Active Botswana –male and female, age 18-29, daily tenofovir, N = 1200 Multi-country eastern/southern Africa –female, age >18, daily tenofovir India –MSM, age > 18, daily truvada Multi-country –discordant couples, age >18, truvada, vs tenofovir Multi-country eastern/southern Africa (development) –Vaginal tenofovir vs PrEP microbicide

PrEP Study: Proposed Multi-country eastern/southern Africa plus US –female, age 16-22, Africa –male MSM, age 16-22, US –episodic vs daily truvada

Adolescent Specific Issues for PrEP No biological issues Need sexually active populations screening in approaches parental permission approaches Need for behavioral studies around use patterns

Summary Plenty of Challenges !